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Abstract
Objective—The Recovery Management paradigm provides a conceptual framework for the
examination of joint impact of a focal treatment and post-treatment service utilization on
substance abuse treatment outcomes. We test this framework by examining the interactive effects
of a treatment for comorbid PTSD and substance use, Seeking Safety, and post-treatment Twelve-
Step Affiliation (TSA) on alcohol and cocaine use.
Method—Data from 353 women in a six-site, randomized controlled effectiveness trial within the
NIDA Clinical Trials Network were analyzed under latent class pattern mixture modeling.
LCPMM was used to model variation in Seeking Safety by TSA interaction effects on alcohol and
cocaine use.
Results—Significant reductions in alcohol use among women in Seeking Safety (compared to
Health Education) were observed; women in the Seeking Safety condition who followed up with
TSA had the greatest reductions over time in alcohol use. Reductions in cocaine use over time
were also observed but did not differ between treatment conditions nor were there interactions
with post-treatment TSA.
Conclusions—Findings advance understanding of the complexities for treatment and continuing
recovery processes for women with PTSD and SUDs, and further support the chronic disease
model of addiction.
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Introduction
Nearly 90% of women who present for substance abuse treatment report lifetime exposure to
trauma (Dansky, Saladin, Brady, Kilpatrick, & Resnick, 1995; Lincoln, Liebschutz,
Chernoff, Nguyen, & Amaro, 2006; Mills, Lynskey, Teesson, Ross, & Darke, 2005;
Najavits, Weiss & Shaw, 1997; Reynolds, Hinchliffe, Asamoah & Kouimtsidis, 2011).
Between 30–60% of these women present with co-occurring PTSD and substance use
disorders (Brady, 2001; Chilcoat & Menard, 2003; Donovan, Padin-Rivera, & Kowaliw,
2001; Najavits, Weiss, & Shaw, 1997; Triffleman, 2003). Treatment for co-occurring
substance use disorders (SUD) and PTSD has been particularly challenging, as these patients
have greater rates of relapse and higher rates of repeated service use compared to patients
with either of the two disorders alone (Back, 2010; Cottler, Compton, Mager, Spitznagel, &
Janca, 1992). Current treatment recommendations for comorbid PTSD and SUDs underscore
the importance of an integrated therapeutic approach rather than a “split” approach in which
an individual is treated for the trauma first and then the addiction or vice versa (Foa, Keane,
& Friedman, 2000; Jacobsen, Southwick, & Kosten, 2001).
Seeking Safety as an Integrative Treatment
Seeking Safety is an intervention that was developed as a cognitive–behavioral therapy
specifically designed to address the co-occurrence of PTSD and SUDs among women with
trauma experiences (Najavits, 2002). Seeking Safety has been examined in a number of
contexts and populations (e.g., female veterans, low income urban women, adolescent girls)
(Desai, Harpaz-Rotem, Najavits, & Rosenheck, 2008; Hien, Cohen, Miele, Litt, & Capstick,
2004; Najavits, Gallop, & Weiss, 2006) and in multiple types of designs (e.g., controlled
trials and non-randomized pilot studies; Cook, Walser, Kane, Ruzek, & Woody, 2006; Gatz
et al., 2007; Najavits, Weiss, Shaw, & Muenz, 1998; Zlotnick, Najavits, & Rohsenow,
2003). Seeking Safety has been linked to significant decreases over time in substance use
disorders, with these decreases being greater than treatment-as-usual and comparable to
relapse prevention (Hien et al., 2004). However, in a separate multisite hybrid (i.e.,
combined efficacy/effectiveness; Rounsaville, Carroll & Onken, 2001) clinical trial within
the National Institute on Drug Abuse’s Clinical Trials Network (Hien, Wells et al., 2009),
Seeking Safety had no impact on substance use outcomes among the overall, intent-to-treat
sample. Thus, studies which can elucidate the factors that may influence when and for whom
this treatment is most effective (or ineffective) with respect to substance use outcomes are
crucially needed.
Evaluating Post-Treatment Outcomes: Recovery Management
The justification for examining the joint impact of integrative PTSD and SUD treatments,
such as Seeking Safety, and services outside of the formalized behavioral treatment context
emerges from the Recovery Management paradigm. Proponents of this perspective have
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suggested that several factors, including adjunct recovery services that are unrelated to the
focal treatment (particularly in outpatient settings), can influence or modify treatment
outcomes in relation to the services that individuals received in treatment. The impact of
factors that are unrelated to a focal treatment protocol can grow exponentially, even as
patients are far-removed from the formalized treatment context (McLellan, Chalk & Bartlett,
2007; McLellan, McKay, Forman, Cacciola, & Kemp, 2005; Scott & Dennis, 2009).
McLellan et al., (2007) alluded to this quandary, stating “how far treatment programs can go
in supporting recovery before extra-treatment related recovery services become primary in
the recovery process will probably be dependent on many factors” (p.333).
As the fields of substance abuse treatment and health services move toward a continuing
care model, the designs of SUD treatment trials, and treatment of comorbid PTSD and SUDs
in particular, will need to incorporate evaluations of the primary treatment, as well as extra-
treatment related recovery services. Incorporating a continuing care model in the context of
behavioral therapies development and in the evaluation of larger systems of care falls within
a larger impetus for advancing treatment and health services research to increase the
connection between research and practice (Laudet, 2008).
Twelve-Step Affiliation Programs as Adjuncts to Addictions Treatment
For patients who have substance use disorders in the absence of PTSD, several studies have
shown Twelve-Step Affiliation (TSA) (e.g, Alcoholics Anonymous or Narcotics
Anonymous) is a strong prognostic indicator associated with better substance use outcomes
(Chi, Kaskutas, Sterling, Campbell & Weisner, 2009; Kaskutas, 2009; Morgenstern,
Labouvie, McCrady, Kahler, & Frey, 1997; Project MATCH, 1998; Scott & Dennis, 2009;
Ye & Kaskutas, 2009); this also suggests promise for TSA as a potential form of continuing
care that supplements and/or enhances the effects of outpatient treatment. TSA may serve to
sustain beliefs and commitment to specific abstinence-related goals, enhance active coping
efforts, and provide emotional support in a context that encourages abstinence (Ouimette et
al., 2001; Ouimette, Moos, & Finney, 1999, 2000; Winzelberg & Humphreys, 1999).
Although there is evidence suggesting the positive effects of TSA extend to populations with
PTSD and SUDs 2-to-5 years post-intervention, particularly among male combat veterans
(Ouimette et al., 2003), relatively few studies have examined the impact of TSA in concert
with outpatient treatment on PTSD and SUD treatment outcomes. Further, studies of PTSD
and SUD treatment efficacy targeting women have not examined the impact of extra-
treatment recovery supports in the context of receiving active treatments and their
corresponding outcomes.
Treatment by Attendance Moderation Effects—Evidence is also emerging that
treatment attendance can moderate treatment efficacy and effectiveness. In fact, recent work
that has examined both observed (Barkham, Connell, Stiles, Miles et al., 2006) and latent
attendance patterns (Hien, Morgan-Lopez, Campbell, Saavedra et al., in press; Morgan-
Lopez & Fals-Stewart, 2007) has suggested that attending around half of available sessions
may be optimal, at least among patients who self-select their treatment dosage (Feaster,
Newman & Rice, 2003). It has been suggested that patients in treatment may mutually
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regulate their level of improvement and the duration of treatment to reach their own personal
level of optimal functioning (Barkham et al., 2006); conversely, attendance at all sessions,
particularly for women with comorbid PTSD & SUDs, may be related to greater post-
treatment impairment (Najavits, Weiss, Shaw & Muenz, 1998) and may require some form
of post-treatment aftercare such as TSA.
The purpose of the current study is to examine the additive and interactive effects between
Seeking Safety and post-treatment TSA and how these effects vary across treatment
attendance patterns. Many women who experience interpersonal trauma, if treated for
resulting PTSD and/or substance abuse problems, have to return to the very context (e.g.,
family, significant other, etc.) in which the trauma occurred (Mohr, Averne, Kenny, & Del
Boca, 2001; Norman, Tate, Anderson, & Brown, 2007; Tate, Brown, Unrod, & Ramo, 2004;
Saladin et al., 2003). Seeking Safety emphasizes, among other topics, the concept of carving
out a safe place for one’s self during and after treatment. TSA programs have the potential to
provide women with an environment that will be supportive of their recovery from
substance use beyond the outpatient context. Furthermore, an analysis of whether Seeking
Safety and post-treatment TSA have joint additive effects (i.e., independent main effects) on
alcohol and cocaine use or whether Seeking Safety may interact with TSA a) fits well within
the tenets of the Recovery Management paradigm (e.g., McLellan et al, 2005; 2007) and b)
is consistent with data on positive treatment outcomes for TSA for patients with PTSD and
SUDs (Laudet, 2008; Ouimette et al., 2001; 2003). Thus, the present study aims to re-
analyze the NIDA Clinical Trials Network (CTN) “Women and Trauma” data to specifically
examine differential substance treatment outcomes for those receiving Seeking Safety
compared to those receiving a health education control intervention. Unlike previous
evaluations of Seeking Safety, we simultaneously account for a) participation in post-
treatment TSA as a potential moderator of post treatment outcome trajectories (Scott &
Dennis, 2009) and b) variation in treatment outcome by patterns of attendance and group




Participants were 353 women receiving community-based, intensive, outpatient substance
abuse treatment from six geographically diverse programs across the United States.
Participants were eligible for the study if they reported at least one lifetime traumatic event
and met DSM-IV criteria for either full or subthreshold PTSD in the past 30 days. Sub-
threshold PTSD differed from full PTSD only in the number of symptom clusters that
needed to be present; that is they had to meet criteria B (re-experiencing the trauma) and
either criteria C (avoidance of trauma reminders) or D (hyperarousal) instead of both. Other
inclusion criteria were: 1) being a female; 2) 18–65 years of age; 3) using alcohol or illicit
substances within the past six months; and 4) meeting a current (within the prior year)
diagnosis of drug or alcohol abuse or dependence. Women were excluded if they had: 1)
impaired mental cognition; 2) significant risk of suicidal/homicidal behavior; 3) history of
schizophrenia-spectrum diagnosis; or 4) a history of active (past two months) psychosis.
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Recruitment occurred over 21-months in 2004 and 2005. Interested treatment program
clients were assessed for eligibility during a screening assessment and then completed a
baseline interview. After the baseline assessment, participants were randomized into one of
two treatment groups: Seeking Safety or an active control condition, Women’s Health
Education. Women completed brief, weekly assessments for substance use, PTSD
symptoms, and service utilization during treatment and were reassessed using the full
assessment battery 1-week, 3-, 6-, and 12-months post treatment.
The average age of participants was 39.2 (s.d. = 9.3) with 45% Caucasian, 34% African-
American, 6% Latina and 13% Multi-racial. Thirty-six percent of participants were single
and 46% of participants were separated or divorced. Eighty percent of participants met
criteria for Full PTSD and the majority of women reported lifetime physical and/or sexual
abuse (see Table 1). Descriptives for treatment attendance, TSA attendance and ASI-Lite
substance use outcomes across both treatment conditions are shown in Table 2.
Study Treatment
Treatment consisted of two 90-minute sessions per week for 6 weeks. Groups ranged in size
from two to eight women and operated with an open, rolling admission so that participants
entered the group at any point in the 12-session cycle (i.e., a participant might enter the
group at session 7 and complete treatment with session 6). The general protocol was for
participants to remain in the study treatment regardless of attendance unless they missed
four consecutive sessions with no study contact but these participants were still encouraged
to participate in the 1-week, 3-month, 6-month and 12-month post-treatment follow-up
assessments.
Seeking Safety Treatment (Najavits, 2002)—Seeking Safety, a short-term manualized
therapy, applies cognitive-behavioral strategies to the goals of reducing substance use and
the negative impact of trauma exposure and was developed for use with both individuals and
groups. Sessions are structured and include basic education on substance use disorders and
PTSD, action skills to prevent drug use and control PTSD symptoms, cognitive restructuring
with particular attention to maladaptive thoughts associated with substance use and trauma
symptoms, and a focus on relationship issues and developing effective communication skills
to build a healthy support network. Session topics are appropriately adapted to address
participant’s immediate reports of unsafe behavior and coping skills. The group format
allows for women to discuss the application of coping skills in their lives and participants
provide support and reinforcement to each other.
Women’s Health Education (Miller, Pagan, & Tross, 1998)—Women’s Health
Education is a psychoeducational intervention that focuses on topics such as female
anatomy, human sexual behavior, pregnancy and childbirth, nutrition, and diabetes.
Women’s Health Education provides facilitator attention, expectancy of benefit, and an issue
oriented focus equivalent in attention to Seeking Safety, but does not provide theory driven
techniques such as cognitive behavioral therapy and psychoeducation specific to substance
abuse and PTSD. Topic presentations use mini-lecture, video, story-telling and/or text
readings, as well as exercises to facilitate group discussion and application of materials.
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Substance Use—Alcohol and cocaine use were collected for the prior 30-days using the
Addiction Severity Index-Lite (ASI-Lite, revised from the fifth edition of the ASI; McLellan
et al., 1992). Assessments were taken at baseline, 1 week post-treatment, and at 3-, 6- and
12-month follow-ups; the key outcomes were binary indicators of any use of each substance
in the past 30 days.
Twelve-Step Affiliation—The post-treatment TSA measure from the Non-Study Medical
Services (NSMS) instrument, a brief interview eliciting the variety and intensity of services
received after study treatment. The one week follow-up measure asks participants how many
times since their last assessment they attended Twelve-Step or Self-Help meetings; however,
the 3-, 6- and 12-month follow-up measures asked how many times in the past 30 days they
attended Twelve-Step or Self-Help meetings. In order to put the measures on a common
metric, the total number of days they attended was divided by either the number of days that
had passed since their previous assessment (1-week FU) or divided by 30 (3, 6 and 12 month
FU) which captures the proportion of the possible days attended during the period in
question.
Model Description
As noted elsewhere (Morgan-Lopez & Fals-Stewart, 2006; 2007; 2008a; 2008b), standard
analytic approaches used for modeling treatment outcomes (e.g., repeated measures
ANOVA, group-clustered latent growth models) have limited utility in accounting for the
changes over time in treatment group membership (i.e., loss and addition of group members)
that occur within open enrollment groups. Group-clustered latent class pattern mixture
modeling (LCPMM; Lin, McCulloch, & Rosenheck, 2004; Roy, 2003; see also Muthén, Jo,
& Brown, 2003) has been shown in both real (Morgan-Lopez & Fals-Stewart, 2007) and
simulated treatment outcome data (Morgan-Lopez & Fals-Stewart, 2008b) to be a promising
approach for modeling specific nuances of the open enrollment group process (i.e., group
membership turnover, latent attendance classes within treatment groups).
LCPMMs account for (a) variability in the treatment effect across a finite number of latent
attendance classes among individuals in the same treatment group and (b) can be structured
to model relations between attendance class membership and variation in patients’ points of
entry into treatment. The logic underlying the utility of LCPMMs to the analysis of data
from substance abuse treatment trials with rolling/open enrollment groups is that, within any
point of the trial, the proportions of different types of attendance patterns (and, therefore,
different subtypes of patients) are allowed to vary at any given slice in time at which the trial
is running (Morgan-Lopez & Fals-Stewart, 2007, 2008a). Moreover, as group composition
and norms change over time, in concert with changes in the membership of the group (e.g.,
the proportion of dropouts decreases over time as the group becomes more cohesive), it may
affect the efficacy of the treatment during particular periods of the history of the group; we
do note that, it would not be expected that the same level of group cohesion would occur as
would be the case with closed groups (see e.g., Morgan-Lopez & Fals-Stewart, 2006 for an
extended discussion).
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The focal point of the LCPMM model is a categorical latent variable (called “Attend” in
Figure 1) which represents membership in one of a finite number of latent classes (e.g.,
Attend = 1, 2…..C). This variable represents multiple hidden subpopulations within
treatment outcome data which will vary between-classes along three sets of variables (see
Figure 1). First, classes can vary in their probabilities of treatment attendance, which are a
series of binary indicators of whether each patient showed up (0 = no-show, 1 = show)
beyond the initial session for each person. Second, differences may emerge on the
distributions of the timing of treatment entry (i.e., “Start Week”) which may show (a)
fluctuations over time in the proportions of patients from each sub-population and (b) be
indicative of variation in the makeup of treatment groups that is dependent on calendar time
(Morgan-Lopez & Fals-Stewart, 2007, 2008b). Finally, the treatment effects on growth over
time in the outcome for the in-treatment (βITI) and post-treatment (βPTI) slopes that underlie
the substance use outcome measures (ybaseline-y12 month) may depend on (i.e., interact with)
latent attendance class membership.
The model also includes a continuous latent variable called “TSA” (Twelve-Step
Affiliation), with indicators that are repeated measures of participation in Twelve-Step
meetings from 1-week through 1-year post treatment1. Initially, a parallel growth process
was explored with these TSA indicators but there was insufficient variability in slopes over
time on TSA to warrant such a model. Instead, a random intercept structure was used for the
TSA indicators which essentially models a weighted average (with the factor loadings
serving as weights) of the number of times in the past month patients attended Twelve-Step
meetings across all four post-treatment time points. The continuous latent TSA variable
served as a) a within-class predictor of changes over time in substance use and b) a within-
class moderator of the post-treatment Seeking Safety/Women’s Health Education treatment
effect. Any potential covariance between treatment condition (SS/WHE) and post-treatment
TSA was also modeled to address potential confounding (though this covariance would turn
out to be non-significant).
While class-specific effects are of interest, overall effects (combined across classes) are also
examined. If there is more than one class, the growth parameters (i.e., conditional growth
parameter means, treatment effects) from each class are averaged and weighted by the class
proportions and standard errors are calculated using the delta method (see Hedeker &
Gibbons, 1997, p.74–76, Morgan-Lopez & Fals-Stewart, 2007, p.593) in order to estimate
the overall treatment effect; note that this weighted averaging can now be conducted in a
single step within an LCPMM analysis (e.g., via the Model Constraint command in Mplus
v5.2). Both overall and class-specific treatment effects will be presented here.
1Measures of in-treatment TSA were not included in the models because the conceptual model implied by the Recovery Management/
Continuing Care paradigms speaks more specifically to the impact of post-treatment services rather than in-treatment services.
However, we examined the impact of in-treatment TSA (and in-treatment interactions with Seeking Safety) on in-treatment changes in
alcohol and cocaine outcomes using both conventional (group-clustered) latent growth models and (group-clustered) LCPMMs. Under
both analytic frameworks (and controlling for Seeking Safety and the SS x TSA interaction), in-treatment levels of TSA were related
to baseline levels of cocaine (p<.001) and alcohol use (p=.027). However, in-treatment TSA levels were unrelated to in-treatment
changes over time in alcohol and cocaine use (ps>.88). As a result, in-treatment measures of TSA were not included in the main
analysis models.
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Preliminary Identification of Functional Form
The group stratified finite mixture modeling facilities within Mplus 5 (Muthén & Muthén,
1998–2009) were used for all analyses under robust maximum likelihood estimation (i.e.,
Mplus MLR estimation under stratification; Asparhouov, 2005). Prior to fitting the models
of interest, the observed proportions for alcohol and cocaine use across pre-intervention and
the four follow-up assessments were plotted in order to get a sense of the optimal functional
form. Bauer and Curran (2004) notes that, in addition to modeling the correct functional
form of the relation between time and repeated measures, ensuring that theoretically relevant
non-linear relations between predictors and growth parameters (e.g., Seeking Safety x TSA
interactions) are modeled can minimize the likelihood of overextraction of latent classes. It
was concluded, based on the graphical analyses that the optimal functional form for the two
substances was piecewise linear with two distinct periods of growth: a) pre-intervention to 1
week follow-up and b) 1-week follow-up through 12 month follow-up. The timesteps for
each of these three growth parameters (intercept, 1st slope, 2nd slope) were structured such
that the intercept was set at pre-intervention levels (i.e., estimated level probability of use in
the week prior to the participant’s 1st treatment session).
Graphical analyses were supplemented by a series of unconditional growth models (with
logit link functions for categorical outcomes for this and all subsequent analyses) examined
under alternate functional forms. Using χ2 difference testing, the fit of the above-described
unconditional two-piece piecewise linear model did not differ significantly from
unconditional models which included a quadratic growth factor for growth during the post-
treatment phase (Δ χ2 for all three substances at or exceeding p = .10). Thus, the two-piece
piecewise linear functional form was used for all subsequent analyses.
Identification of Optimal Number of Attendance Classes
Next, a series of two-piece linear (group-stratified) LCPMMs with logit link functions, with
varying numbers of latent attendance classes, was fit to determine the optimal number of
classes. Bayesian Information Criterion (BIC) and entropy were used to determine the
optimal number of classes. While the Bootstrap Likelihood Ratio Test (BLRT) had been
recommended for determining the optimal number of classes for mixture models (Nylund,
Asparouhov & Muthén, 2007), very recent work suggests that the BLRT is sub-optimal, and
the BIC optimal, for mixture models in the presence of covariates (Nylund-Gibson &
Masyn, 2009). As shown in Table 3 the BIC suggests 3 classes are optimal across both the
alcohol and cocaine models.
Probabilities of treatment attendance across classes—Across the two sets of 3-
class LCPMM analyses, a similar pattern emerged for treatment attendance (only patterns
from the alcohol model are shown to avoid redundancy). The first class, called
“Completers”, never decreased below a 90% probability of treatment attendance; the class
membership (based on posterior probabilities of class membership as opposed to the most
likely class assignment) was between 30–31% of the total sample across both substances.
The second class under the 3-class models is called “Dropouts”. This class never exceeded a
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41% probability of attending treatment and by the 4th session they would have attended,
they had virtually 0 probability of attendance for the remainder of the protocol; this class
made up around 27% of the sample across both substances. The third class is referred to as
the “Titrators” class. Through the 7th session, Titrators ranged between a 50–80%
probability of attending treatment, with further decreases in the probability of showing up
for treatment across sessions, but with probabilities that never approached 0 as in the
Dropout class; this class ranged between 42–43% of the sample across both substances.
In addition to preliminary analyses for minimizing the extraction of spurious classes,
additional confidence in the number and structure of the classes from the LCPMM models
come from a) auxiliary information such as previous work and b) substantive theory
regarding the number of classes and class structure (Muthén, B.O., 2003). First, it is noted
that the number and structure of these classes is consistent with other studies using LCPMM
for modeling attendance patterns and treatment outcome trajectories jointly in independent
datasets (e.g., Morgan-Lopez & Fals-Stewart, 2007). Further, the notion of classes of
individuals who attend most sessions (Completers) and drop out of studies early (Dropouts)
is a staple of all treatment outcome research while classes of individuals who self-titrate
their treatment dosage is also common in AOD treatment (Barkham et al., 2006; Feaster,
Newman & Rice, 2003).
Distributions of the Month of Trial Entry—The histogram (alcohol model only) in
Figure 2 shows fluctuation in the number of patients within each class in the three-class
model(s) throughout the 22 month span of calendar time for recruitment into the trial. As
noted earlier, the overall split in class membership in this analysis was around 30%
Completers/26% Dropouts/44% Titrators; this is in contrast with a class membership
structure of 48% Completers/24% Dropouts/28% Titrators for recent analyses of these data
that did not incorporate indicators of TSA into treatment outcome analyses (Hien et al.,
2012). Prior to Month 10, Dropouts made up 34% of the sample but only 19% of the sample
beyond Month 10 suggesting lower dropout probabilities during the second half of the trial;
conversely, “Titrators” made up 36% of the sample from Months 1–10 and increased to 50%
beyond Month 10. Further, in comparing the most likely class memberships from the current
analysis with the recent re-analysis, there appeared to be four types of patients in general: 1)
patients whose most likely class membership was Completers in both analyses (30%), 2)
patients whose most likely class membership was Titrators in both analyses (22%), 3)
patients whose most likely class membership was Dropout in both analyses (22%) and 4)
patients whose class membership was Completers in the main outcomes analysis but were
Titrators in the current analysis (20%).
Model Results
Overall (weighted-averaged) effects are emphasized in the text and described in detail while
within-class treatment effects are shown in Table 5. Across all classes, latent post-treatment
TSA was not significantly related to post-treatment alcohol use (p = .27) and cocaine use
over time (p = .29). Also, treatment condition was unrelated to post-treatment TSA (p = .97).
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Alcohol Model—Overall, there were significant in-treatment decreases in the rates of
alcohol use within the WHE condition (b = -.581 (.296), t = −1.96, p=.050); however, the
differences between Seeking Safety and WHE in-treatment slopes were non-significant (p=.
30). The treatment intervention by post-treatment TSA interaction was significant, b =
−2.888 (SE = . 933), t = −3.094, p = .002. This result suggests that the largest decreases in
alcohol use rates over time were for women in the Seeking Safety condition who also had
greater usage of post-treatment TSA.
A variant of simple slopes analysis (Aiken & West, 1991) was used to assess Seeking
Safety/Women’s Health Education differences on the post-treatment slope for alcohol use at
specific levels of TSA (15% and 65%2 of available TSA sessions; mean at 1-week post-
treatment = 41% of possible sessions); TSA indicators were re-centered to reflect 0 points of
15% and 65% respectively and then models were re-analyzed to assess changes in the
SS/WHE treatment effect across levels of TSA. For “low” post-treatment TSA utilization,
the post-treatment slope within WHE showed non-significant increases in the rates of
alcohol use, b = .120 (.089), t = 1.343, p=.18, with no differences between Seeking Safety
and WHE changes in rates, b = .215 (.562), t = .382, p=.70. For “high” post-treatment TSA
utilization, the post-treatment slope within WHE showed significant post-treatment
decreases in the rates of alcohol use, b = −1.578 (.159), t = −9.921, p<.001, with
significantly steeper decreases in alcohol use rates for women in Seeking Safety, b = -.842 (.
313), t = −2.688, p=.007; based on class-specific estimates, it appears that the overall
Seeking Safety x post-treatment TSA interaction effects are driven by significant class-
specific interaction effects in both the Completers class (p<.05) and the Dropouts class (p<.
001).
Cocaine Model—For cocaine, there were in-treatment reductions in the rates of cocaine
use (b = -.756 (.384), t = −1.970, p=.049), followed by further non-significant decreases in
the rates of cocaine use (p=.11). However, neither in-treatment nor post-treatment treatment
differences in slopes were observed between Seeking Safety and WHE (ps>.20) on cocaine
use nor were any interactions with post-treatment TSA observed (p=.93).
Discussion
The present study re-analyzed the CTN “Women and Trauma” study data and examined
differential substance abuse treatment outcomes for those receiving Seeking Safety
compared to Women’s Health Education accounting for moderating effects of participation
in post-treatment TSA and modeling attendance patterns and membership turnover.
Evaluation of integrative treatments among patients with comorbid PTSD and SUDs may
benefit from a chronic care perspective that moves beyond a singular focal treatment to
better capture the recovery process (Dennis, Foss, & Scott, 2007; McLellan et al., 2005;
Scott, Foss, & Dennis, 2005; Scott, Dennis, & Foss, 2005). To date, studies on PTSD and
2Though a formal “regions of significance” test was not conducted, a series of simple slopes analyses were conducted to assess post-
treatment treatment effects of Seeking Safety on alcohol use at 10% increments for TSA. From these analyses, it was revealed that
statistically significant differences between Seeking Safety and Women’s Health Education emerged at the point where patients were
attending at least 60% of the available TSA sessions.
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SUD treatment efficacy and effectiveness targeting women, such as Seeking Safety, have
not examined the potential complimentary impact of extra-treatment recovery supports.
At the average rate of post-treatment TSA, significant reductions in substance use were
observed that were specific to the attendance pattern (Completer, Titrator or Dropout) and
the substance (alcohol or cocaine) for women in Seeking Safety compared to Women’s
Health Education. On average, significant reductions in rates were observed for alcohol use
among women in Seeking Safety (compared to Women’s Health Education) who were in the
Completers and Titrators class, with treatment effects on cocaine approaching significance.
However, several important interaction effects between Seeking Safety and post-treatment
TSA were observed, whereby women in Seeking Safety who also sought post-treatment
TSA generally were observed to have the greatest benefits; in some cases, and across some
classes, women who were in Seeking Safety and who did not follow up with TSA post-
treatment actually saw worse substance use outcomes compared to those in Women’s Health
Education. These findings, where some women benefit from the synergy between Seeking
Safety and TSA, and those who did not receive TSA did more poorly without it, may
provide an explanation of why evaluations of treatments for PTSD and SUDs have shown
mixed findings (e.g., McGovern, Lambert-Harris, Acquilano, Xie, & Weiss, 2009).
Consideration of the full complexities of open enrollment trials are essential to be able to
detect more subtle patterns of treatment response that may be diluted in head to head
comparisons that do not incorporate patterns of services and impact of extra-treatment
recovery supports (Dennis, Perl, Huebner, & McLellan, 2000).
Capturing the joint impact of formalized outpatient treatment and extra-treatment recovery
supports that occur post-treatment also reflects the chronic care perspective on SUDs, where
the joint impact of a focal treatment and post-treatment recovery services may be more
efficacious than outpatient treatment without follow-up services (Laudet, 2008; Morgenstern
et al., 1997; Scott & Dennis, 2009). Although it might be the case that women who reported
attending post treatment TSA may also be more motivated and invested in continuing
recovery, several aspects of TSA are likely to facilitate maintenance of treatment gains.
First, TSA programs are highly accessible and are the most common form of aftercare in this
population relative to the limited availability of other long-term addiction services. Second,
TSA programs offer social support, ongoing connection to treatment with less commitment
required, and are delivered in groups of women (and men) with similar problems and similar
goals. Third, TSA complements what women learned in Seeking Safety; in particular,
Seeking Safety emphasizes the concept of carving out a safe place for one’s self during and
after treatment. Ruptures in intimate partnerships, family and other social supports are a
frequent consequence of addiction, traumatic stress, and other comorbidities; re-engaging
these important supports is often critical to successful recovery.
TSA programs may provide a place for women to seek and receive support for their
recovery from substance use and, presumably, their trauma experiences. TSA also is likely
to be comprised of individuals with similar histories of comorbid psychiatric disorders
(Bogenschutz, Geppert & George, 2006). In many cases, given the preponderance of women
in this population who have to return to the very environment in which the traumatic events
occurred, TSA groups may be one of the few safe places these women have, assuming they
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can feel safe within a TSA group. This is noteworthy, because it may speak to the
importance of considering the gender mix of the TSA group in which women enter after
outpatient treatment, because women with interpersonal trauma histories who avoid AA/NA
may be more likely to do so if the groups are male-dominated. Women tend to make up 20–
35% of AA/NA groups (Alcoholics Anonymous, 2005; Kelly, Stout, Tonigan, Magill &
Pagano, 2010), but the extent to which the male-to-female ratio within TSA groups impacts
a) variation in women’s entry into, and outcomes from, TSA groups remains to our
knowledge an open question.
Women in the Seeking Safety condition who did not attend TSA post treatment were at
higher risk for increased substance use. Seeking Safety focuses on trauma-related issues and
PTSD symptoms. If women lack social supports or other connections post-treatment to help
continue the management of trauma-related and/or recovery-related issues, there may be
increased risk of relapse. The significant deterioration experienced by women who received
Seeking Safety but did not report post-treatment TSA may be related to post-treatment
relapse as women cope without support offered by group members striving for similar goals
and return to primary contexts where, in many cases, the trauma is still very salient (Mohr et
al., 2001).
Clinical Implications and Future Directions
The present study extends current knowledge on treating conditions with high risk for
relapse, such as PTSD and comorbid SUDs, and the adjunctive benefits of TSA for
extending treatment effects. Findings underscore the importance of maintaining an ongoing
connection to some form of recovery services and the need for continued social support,
particularly among a population of women who are most vulnerable. More generally, the
results of the present study highlight the need for behavioral clinical trials to examine
contextual factors such as managing post-study treatment addiction recovery a priori in
order not to obscure critically important findings. TSA reinforces commitment to specific
abstinence-related goals, and provides emotional support in a context that encourages
abstinence. Paired with insight and skills learned in Seeking Safety, following treatment up
with TSA may help women with trauma manage their substance symptoms more effectively.
Our findings suggest that providers may consider the use of TSA in combination with
Seeking Safety to promote potential synergistic effects, or the trauma specific aspects of
Seeking Safety could possibly be adapted to incorporate more directly the principles of
TSA.
Limitations—Evaluation of the findings from the present study should take certain
limitations into consideration. First, TSA was not systematically randomized, as participants
self-selected into TSA post-treatment. It should be noted however, there was no relation
between treatment condition and TSA and thus this “self-selection”, and factors potentially
related to self-selection (e.g., motivation), did not differ across the Seeking Safety and WHE
conditions. This would be particularly true if in-treatment attendance and post-treatment
TSA were in- and post-treatment proxies for motivation (i.e., more motivated patients went
to more treatment sessions and more TSA sessions). Second, the present study only focused
on self-reported post-treatment TSA attendance. Although attendance is indeed an important
Morgan-Lopez et al. Page 12






















indicator of participation in TSA, and several interaction effects were observed on post-
treatment outcomes, collection of richer process-related TSA measures that consider level of
engagement and involvement were not assessed in the present study and should be examined
in future studies.
Despite these limitations, the present study advances our understanding of the complexities
involved in the treatment and continuing recovery process for women with PTSD and SUDs.
These data support integrative outpatient treatment that is specific to treating PTSD and
SUDs simultaneously (Najavits, 2002) and to encourage contact with post-treatment services
that may provide a continuously safe and supportive recovery community.
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Appendix 1
CONSORT Statement Checklist for Reporting a Randomized Trial
PAPER SECTION
And topic




1 How participants were allocated to interventions (e.g.,








2 Scientific background and explanation of rationale. 3–6
3 Eligibility criteria for participants and the settings and
locations
where the data were collected.
6–8
4 Precise details of the interventions intended for each group
and how




5 Specific objectives and hypotheses. 7
6 Clearly defined primary and secondary outcome measures
and, when applicable, any methods used to enhance the
quality of
measurements (e.g., multiple observations, training of
assessors).
9–10
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Item Descriptor Reported on
Page #
Sample size 7 How sample size was determined and, when applicable,
explanation









8 Method used to generate the random allocation sequence,
including
details of any restrictions (e.g., blocking, stratification)
Hien 09
9 Method used to implement the random allocation sequence
(e.g., numbered containers or central telephone), clarifying
whether the
sequence was concealed until interventions were assigned.
Hien 09
10 Who generated the allocation sequence, who enrolled
participants,
and who assigned participants to their groups.
Hien 09
11 Whether or not participants, those administering the
interventions,
and those assessing the outcomes were blinded to group
assignment.
If done, how the success of blinding was evaluated.
8
Statistical methods 12 Statistical methods used to compare groups for primary
outcome(s);






13 Flow of participants through each stage. Specifically, for
each group
report the numbers of participants randomly assigned,
receiving
intended treatment, completing the study protocol, and
analyzed for
the primary outcome. Describe protocol deviations from
study as





14 Dates defining the periods of recruitment and follow-up. 7
15 Baseline demographic and clinical characteristics of each
group.
Table 1
16 Number of participants (denominator) in each group
included in
each analysis and whether the analysis was by "intention-to-
treat".





17 For each primary and secondary outcome, a summary of
results for
each group, and the estimated effect size and its precision.
15–20
18 Address multiplicity by reporting any other analyses
performed,
including subgroup analyses and adjusted analyses,
indicating those





19 All important adverse events or side effects in each
intervention.
Hien 09
20 Interpretation of the results, taking into account study
hypotheses,
sources of potential bias or imprecision and the dangers
associated




21 Generalizability (external validity) of the trial findings. 22–23
22 General interpretation of the results in the context of current
evidence.
20–22
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Seeking Safety by Post-Treatment TSA Interaction Model
Attend = Latent Class Variable. Start Week = Calendar time variable indicating the week of
the trial. AttendanceSession2-Session12 = Binary indicators of treatment attendance from
Session 2 through Session 12. αI = In-treatment intercept. βITI = In-treatment slope. βPTI =
Post-treatment slope. ybaseline-y12month = Repeated substance use outcome measures. TSA =
Continuous latent variable capturing the average TSA attendance across 1 year post-
treatment.
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Histogram of the Week of Trial Entry for each Attendance Class by Calendar Time
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Table 1









Variables Mean(SD) or %
Age (years) 39.2(9.3) 39.3(9.5) 39.0(9.1)
Race/Ethnicity
  African American/Black 34.0 33.0 35.0
  Caucasian 45.6 47.2 44.1
  Latina 6.5 4.0 9.0
  Multi-racial/Other 13.9 15.9 11.9
Education (years) 12.5(2.4) 12.7(2.3) 12.4(2.6)
Employment
  Employed 40.2 40.3 40.1
  Unemployed 55.0 54.6 55.4
  Student/Retired/Disabled 4.8 5.1 4.5
Current Substance Abuse or Dependence
Diagnosis
  Cocaine 70.5 72.7 68.2
  Stimulants 7.7 8.5 6.8
  Opiates 25.6 25.6 25.6
  Marijuana 27.2 27.8 26.6
  Alcohol 56.1 59.7 52.5
PTSD Diagnosis (% meeting full criteria) 80.4 76.7 84.2
Lifetime Traumatic Experiences
  Child Physical Abuse 58.7 61.1 56.3
  Adult Physical Abuse 84.8 83.4 86.2
  Child Sexual Abuse 70.1 73.6 66.7
  Adult Sexual Abuse 67.6 65.1 70.1
  Transportation Accident 72.7 72.2 73.3
  Life Threatening Illness 39.8 41.5 38.1
  Exposed to Violent Death 19.3 16.5 22.2
a
There were no statistical differences between treatment groups on any variable.
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Table 2







  Week 2 .782 .707
  Week 3 .760 .660
  Week 4 .657 .623
  Week 5 .613 .571
  Week 6 .615 .454
  Week 7 .617 .540
  Week 8 .555 .472
  Week 9 .514 .509
  Week 10 .492 .441
  Week 11 .454 .427
  Week 12 .481 .387
TSA Attendance
  1-Week Post-Treatment .415 .440
  3 Months Post-Treatment .328 .335
  6 Months Post-Treatment .285 .275
  12 Months Post-Treatment .203 .225
ASI-Lite Alcohol
  Baseline .477 .418
  1-Week Post-Treatment .285 .304
  3 Month Post-Treatment .341 .276
  6 Month Post-Treatment .334 .374
  12 Month Post-Treatment .405 .348
ASI-Lite Cocaine
  Baseline .409 .356
  1-Week Post-Treatment .243 .269
  3 Month Post-Treatment .250 .227
  6 Month Post-Treatment .210 .244
  12 Month Post-Treatment .256 .268
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Table 3
Global Fit
Bayesian Information Criterion (BIC)
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Table 4
Average Classification Probabilities
Outcome Model Average Posterior Probabilities
Completers Titrators Dropouts
Classes – Alcohol
  Completers .921 .071 .008
  Titrators .075 .870 .054
  Dropouts .027 .049 .925
Classes – Cocaine
  Completers .844 .101 .056
  Titrators .042 .925 .032
  Dropouts .004 .036 .960
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Table 5
Class-Specific Treatment Effect Estimates
Classes
Completers
(31.4% Alc 30.2% Coc)
Titrators
(41.2% Alc 41.9% Coc)
Dropouts
(27.4% Alc 27.9% Coc)
Three-Class Alcohol Model
Intercept −.97(.33)*** −.09(.40) −.13(.45)
WHE I-T Slope −1.98(.54)*** −.25(.31) .53(.84)
WHE P-T Slope .08(.11) −.02(.24) −1.21(1.30)
SS v. WHE: Intercept 1.01 (.66) −.26(.40) .24(.27)
SS v. WHE: I-T Slope .90(.33)*** −.79(.30)** −.78(1.24)
SS v. WHE: P-T Slope .21(.19) −.06(.31) −.61(1.67)
TSA: P-T Slope −.03(.78) −2.22(2.04) −13.52(14.47)
(SS v. WHE) × TSA: PTS −3.36(1.69)* −1.55(1.07) −4.34(.31)***
Three-Class Cocaine Model
Intercept −2.36(.59)*** .50(.64) −1.12(.36)***
WHE I-T Slope −1.53(.30)*** −.59(.42) −.15(.73)
WHE P-T Slope .99(.59) −.11(.43) −4.62(2.62)
SS v. WHE: Intercept .87(.55) −.35(.37) 1.04(.40)
SS v. WHE: I-T Slope −2.74(1.70) −.11(.58) −.37(.46)
SS v. WHE: P-T Slope .78(.47) −.42(.42) 2.90(2.85)
TSA: P-T Slope .69(.66) −2.36(5.60) −23.74(12.56)






SS = Seeking Safety. WHE = Women’s Health Education. I-T = In-Treatment. P-T = Post-Treatment. TSA = Twelve-Step Affiliation.
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